Polyclonal Immunoglobulin for Treatment of Bacterial Sepsis: A Systematic Review

Pildal, Julie; G√łtzsche, Peter C.
July 2004
Clinical Infectious Diseases;7/1/2004, Vol. 39 Issue 1, p38
Academic Journal
Randomized trials of adjunctive treatment of bacterial sepsis with polyclonal immunoglobulin show conflicting results. We performed a systematic review and a meta-analysis of the results of randomized trials that compared reductions in mortality rates in patient groups treated with polyclonal immunoglobulin versus either placebo or no treatment in addition to conventional treatment. High-quality trials had adequate concealment of allocation, were double-blinded and placebo-controlled, and made data available for intention-to-treat analyses. Twenty trials were included. Meta-analysis of all trials showed a relative risk of death with immunoglobulin treatment of 0.77 (95% confidence interval [CI], 0.68-0.88). High-quality trials (involving a total of 763 patients, 255 of whom died) showed a relative risk of 1.02 (95% CI, 0.84-1.24), whereas other trials (involving a total of 948 patients, 292 of whom died) showed a relative risk of 0.61 (95% CI, 0.50-0.73). Because high-quality trials failed to demonstrate a reduction in mortality, polyclonal immunoglobulin should not be used for treatment of sepsis except in randomized clinical trials.


Related Articles

  • Exceptionally Potent Cross-Reactive Neutralization of Nipah and Hendra Viruses by a Human Monoclonal Antibody. Zhongyu Zhu; Bossart, Katharine N.; Bishop, Kimberly A.; Crameri, Gary; Dimitrov, Antony S.; McEachern, Jennifer A.; Yang Feng; Middleton, Deborah; Lin-Fa Wang; Broder, Christopher C.; Dimitrov, Dimiter S. // Journal of Infectious Diseases;3/15/2008, Vol. 197 Issue 6, p846 

    We have previously identified neutralizing human monoclonal antibodies against Nipah virus (NiV) and Hendra virus (HeV) by panning a large nonimmune antibody library against a soluble form of the HeV attachment-envelope glycoprotein G (sGHeV). One of these antibodies, m102, which exhibited the...

  • Efalizumab: A Viewpoint by Helen S. Young and Christopher E.M. Griffiths. Young, Helen S.; Griffiths, Christopher E. M. // American Journal of Clinical Dermatology;2005, Vol. 6 Issue 2, following p119 

    Presents information on efalizumab, a humanized monoclonal antibody that binds a subunit of lympocyte function-associated antigen. Role of efalizumab in the treatment of psoriasis; Recommended dosage of efalizumab in treating patients with psoriasis; Overview of a clinical trial conducted on...

  • Stroke and Death Risk Increased in Severe Sepsis Patients With New-Onset Atrial Fibrillation. Evans, Frederique H. T. // Pulmonary Reviews;Jan2012, Vol. 17 Issue 1, p19 

    The article looks at the increase in stroke and death risk that severe sepsis patients with new-onset atrial fibrillation (AF) are exposed to. Data and analysis gathered in 2007 revealed that severe sepsis patients with new-onset AF had a greater risk for in-hospital stroke, mortality, and a...

  • Declining Case Fatality Rates for Severe Sepsis Good Data Bring Good News With Ambiguous Implications. Iwashyna, Theodore J.; Angus, Derek C. // JAMA: Journal of the American Medical Association;4/2/2014, Vol. 311 Issue 13, p1295 

    The author discusses the study conducted by Kaukonen et al. on intensive care units (ICU) incidence of critically-ill severe sepsis and septic shock in Australia and New Zealand. Tackled are the mortality rates within hospitals from both countries. The significance of longer-term morbidity...

  • Immunological therapy of sepsis: experimental therapies. Arndt, Patrick; Abraham, Edward // Intensive Care Medicine;Feb2001 Supplement 1, Vol. 27, pS104 

    Discusses experimental immunological therapies in sepsis. Modification of immunological pathways that have been examined in clinical trials; Description of the constellation of abnormalities in the patients; Release of platelet-activating factor.

  • The enigma of sepsis. Riedemann, Niels C.; Ren-Feng Guo; Ward, Peter A. // Journal of Clinical Investigation;Aug2003, Vol. 112 Issue 4, p460 

    Discusses the search for effective therapeutic interventions for sepsis. Problems in translational sepsis research; Therapies in development in clinical trials; Historical perspective and definition of sepsis; Description of migration inhibitory factor.

  • Specific IgA antibody response in Ross River virus infection. Carter, I. W. J.; Fraser, J. R. E.; Cloonan, M. J. // Immunology & Cell Biology;Dec1987, Vol. 65 Issue 6, p511 

    Sera were collected over a period of several years from the onset of initial symptoms from 77 patients with Ross River virus infection. When tested for virus-specific IgA antibodies, using an enzyme-linked immunosorbent assay (ELISA) based on antibody class capture, 245 out of 704 sera were...

  • Yes, but will it jump? Butler, Declan // Nature;1/12/2006, Vol. 439 Issue 7073, p124 

    The article focuses on the lack of experimental evidence on the possibility of H5N1 virus to spread from human to human. Many cases of H5N1 cases have gone undetected. There is no antibodies against H5 virus in the blood samples being collected in southern China. The aspects that may contribute...

  • Seroprevalence of Antibody to Varicella Among Somali Refugees. Nysse, Lana J.; Pinsky, Norman A.; Bratberg, Jeffrey P.; Babar-Weber, Azra Y.; Samuel, Terri T.; Krych, Esther H.; Ziegler, Aaron W.; Jimale, Mahamdud A.; Vierkant, Robert A.; Jacobson, Robert M.; Poland, Gregory A. // Mayo Clinic Proceedings;Feb2007, Vol. 82 Issue 2, p175 

    OBJECTIVES: To determine the seroprevalence of varicella anti- body among recent Somali refugees living in Olmsted County, Minnesota, and to estimate the risk of varicella-zoster virus (VZV) infection in this group. SUBJECTS AND METHODS: We obtained blood samples from the study subjects, along...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics